Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of palifermin on reducing
mucositis for patients receiving autologous or allogeneic stem cell transplantation with
supportive care.